US approves first drug for neurotrophic keratitis
US regulators have approved the first drug to treat neurotrophic keratitis, a rare degenerative disease affecting the cornea.
Read More
Tag: Dompe
NICE rejects rare eye disease drug
Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
Read More
EU to review first drug for neurotrophic keratitis
European regulators have agreed to review Italian drugmaker Dompe’s orphan drug Oxervate, opening the door to what may potentially become the first biotech treatment available to patients with the more severe forms of an eye condition called neurotrophic keratitis.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
